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 Introduction 
 Th e use of medications in pregnancy is common and based 
on complex risk-benefi t discussions between physicians and 
patients. 1,2 Unfortunately,  still there are defi cits in the information 
used in the decision making process . Oft en, pharmacokinetic 
(PK) and pharmacodynamic (PD) information for drugs used in 
pregnancy is scanty if present at all. A good example of that is the 
recommendation about the use of oseltamivir for infl uenza. Th e 
Centers for Disease Control and Prevention’s recommendation 
states that no clinical studies have been conducted to assess the 
safety of these medications for pregnant women. However, the 
available risk-benefi t data indicate pregnant women should receive 
prompt therapy. 3 Th is highlights the need for more data regarding 
medication therapy in pregnancy. An annual Conference continues 
to bring together leading researchers and representatives from 
government agencies to discuss this matter. 
 The Third International Conference for Individualized 
Pharmacotherapy in Pregnancy was convened in 2010. Bringing 
together top researchers in the field, the Third Conference 
focused on research and regulatory issues and objectives for 
regulatory agencies as well as specifi c advances in several key 
therapeutic areas. Below are the summaries of the discussions at 
the conference. Full notes from the panel discussions are available 
from the authors on request. Speaker video from the conference is 
available at the PREGMED website:  http://www.pregmed.org. 
 An Overview of the FDA Offi ce of Women’s Health (OWH) 
Funded Pregnancy Studies and Their Impact 
 Th e Food and Drug Administration’s (FDA) Offi  ce of Women’s 
Health (OWH) was created in 1994 aft er the 1992 Government 
Accounting Offi  ce report 4 showed that women were not adequately 
included in clinical studies. Th e FDA OWH mission is to (1) protect 
and advance the health of women through policy, science, and 
outreach, and (2) advocate for inclusion of women in clinical trials 
and analysis of sex/gender eff ects. To that end from 2002 to 2010, 
OWH has funded several studies to address hypertension, anthrax 
prevention, depression, and infection during pregnancy. 
 Th e studies included: PKs and PDs of atenolol during pregnancy 
and postpartum; 5 the PK of amoxicillin during pregnancy and 
postpartum; 6 the PK and PD of sertraline in pregnancy and 
postpartum; 7 the PK and PD of labetalol in pregnancy; and the PK 
and PD of selected antiinfective agents in pregnant women being 
treated for suspected or documented infections. All studies were 
conducted during the second and third trimesters of pregnancy. 
Clearance for all drugs with the exception of azithromycin was 
shown to increase during pregnancy. No data were available on 
ciprofl oxacin. Due to the limited number of subjects in the studies, 
more data are needed in pregnant women. 
 Pregnancy Registries’ Contributions to Informed Clinical 
Practice 
 Pregnancy registries are prospective active data-collection 
systems that can facilitate the early detection of teratogenicity and 
other serious adverse experiences in patients who inadvertently 
or purposefully use a medication or receive a vaccine during 
pregnancy. Th e use of the pregnancy registry design has allowed 
for the collection and analysis of data on the eff ects of drug 
exposure on human pregnancies that have otherwise been 
diffi  cult to obtain. 8 Information from animal studies is useful but 
not always applicable, and pregnant women rarely are enrolled in 
clinical trials. However, useful information about the outcomes 
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 Abstract 
 To address provider struggles to provide evidence-based, rational drug therapy to pregnant women, this third Conference was convened 
to highlight the current progress and research in the fi eld. Speakers from academic centers, industry, and governmental institutions 
spoke about: the Food and Drug Administration’s role in pregnancy pharmacology and the new labeling initiative; drug registries in 
pregnancy; the pharmacist’s role in medication use in pregnancy; therapeutic areas such as preterm labor, gestational diabetes, nausea 
and vomiting in pregnancy, and hypertension; breast-feeding and medications; ethical challenges for consent in pregnancy drug stud-
ies; the potential for cord blood banks; and concerns about the fetus when studying drugs in pregnancy.  The Conference highlighted 
several areas of collaboration within the current Obstetrics Pharmacology Research Units Network and hoped to educate providers, 
researchers, and agencies with the common goal to improve the ability to safely and effectively use individualized pharmacotherapy in 
pregnancy. Clin Trans Sci 2011; Volume 4: 204–209
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of exposed pregnancies can be obtained by the careful collection 
and analysis of postmarketing surveillance data. 
 Pregnancy registries collect reports of exposure during 
pregnancy and, through intensive follow-up with health care 
providers and patients, obtain information about pregnancy 
events and outcomes. Reports are evaluated and outcomes are 
compared to rates in the background population and, if available, 
in subpopulations with the relevant disease states. Reports of 
birth defects are assessed for timing of exposure, maternal age 
and medical history, biologic plausibility, etc. Voluntary reporting 
is known to be subject to various biases and sample size is oft en 
limited in pregnancy registries. Th eir strength lies in their ability 
to obtain and analyze pregnancy outcomes early in the life of a 
product and to evaluate patterns in birth-defect reports. Potential 
birth-defect signals could then be evaluated in studies designed 
for hypothesis testing. 
 The FDA encourages the establishment of pregnancy 
registries for products intended for use by women of childbearing 
potential in its “Guidance for Industry: Establishing Pregnancy 
Exposure Registries” 9 and maintains a list of active registries on 
its website ( http://www.fda.gov/ScienceResearch/SpecialTopics/
WomensHealthResearch/ucm134848.htm ). Pregnancy registries 
can provide periodic (semiannual or annual) summary reports that 
are shared with regulatory agencies that monitor drug safety and 
with health care professionals who request information about use 
in pregnancy. Health care providers and patients who experience 
a drug or vaccine exposure during pregnancy are encouraged to 
request the summary reports and to enroll in pregnancy registries to 
add to the existing data on medication safety during pregnancy. 
 On the Front Lines: A Pharmacist’s Perspective 
 Preliminary data from the National Center for Health Statistics 
regarding 2008 birthrates show a decrease in live births, in 2008 
compared to 2006. However, the live birth-rates per 1,000 women 
increased from 9.4 (2006) to 9.9 (2008) in women 40 to 44 years 
of age and 0.6 (2006) to 0.7 (2008) in women 45 to 49 years of 
age. 10,11 As women age, they are more likely to develop chronic 
medical conditions. Treatment may start before conception. Th ere 
is a need to ensure optimal medication therapy prior to, during, 
and aft er pregnancy to protect the mother and fetus from potential 
side eff ects. Th ese side eff ects may come from medications or 
untreated conditions. When chronically hypertensive women 
become pregnant, maintaining optimal blood pressure (BP) is the 
primary goal, with antihypertensive agents if necessary. 12 In an 
asthmatic pregnancy, continuing current therapy does minimize 
symptoms. Reinforcement of proper inhaler technique, medication 
adherence, control of environmental allergens and coexisting 
medical therapy, as well as smoking cessation, should also be 
emphasized. 13 Diabetics should have preconception counseling 
to help maintain goal blood glucose levels throughout pregnancy. 
A concern in depressed pregnant women is the potential for 
complications if antidepressant therapy is discontinued. Th ese 
women should be advised to continue treatment for their benefi t as 
well as that of the fetus. Treatment includes appropriate nutrition 
and weight gain, treatment of underlying addictions, improving 
mood prior to conception, and routine follow-up. 14 
 When assessing pregnant women with chronic medical 
conditions, a risk/benefi t exists regarding treatment to the patient 
and the fetus. 15 Pregnant women should be educated prior to 
conception, to understand and weigh the risks of the complications 
of their medical condition versus the side eff ects of treatment 
and medications. Once a treatment decision is made, these 
patients should be monitored regularly to ascertain adherence 
to appropriate treatment goals and should be encouraged to utilize 
nonpharmacologic methods when appropriate. 
 A review of maternal/fetal considerations and pharmacotherapy 
of tocolytics for preterm labor 
 In 2006, preterm birth (PTB) complicated 12.8% of pregnancies 
in the United States, with 75% of these births resulting from 
spontaneous preterm labor (PTL) and preterm premature rupture 
of membranes. 10 Long-term sequelae from PTB are more likely to 
occur in neonates born before 32 weeks of gestation and/or weighing 
less than 1,500 g. Th ese sequelae include neurologic handicap, 
blindness, deafness, and chronic respiratory disease. Acute tocolysis 
of PTL is implemented in order to minimize maternal morbidity 
and prolong pregnancy (≥48 hours) by allowing for administration 
of glucocorticoids to hasten fetal lung maturity. Indomethacin, 
nifedipine, and magnesium are three of the more commonly used 
tocolytics. Th e use of tocolytic drugs should be individualized and 
based on the maternal condition, potential for side eff ects, and fetal 
gestational age. 16 In addition, the physiologic changes of pregnancy 
can aff ect the PK and PD of administered tocolytics, which may 
alter the pharmacologic eff ect. 
 Indomethacin is an antiprostaglandin (PG) agent that inhibits 
the synthesis of PGE2 and PGF2α—PGs known to be involved 
in both term and PTL. Although prolonged indomethacin use 
may be associated with vasoconstriction and persistent changes 
in the fetal ductus arteriosus and the developing cerebral, renal, 
and mesenteric circulations, it is the most common prostaglandin 
inhibitor used for tocolysis . With a 50-mg loading dose, the peak 
serum concentration of indomethacin is 2–3 mg/L, half-life (T1/2) 
is 2.2 hours, plasma clearance is 0.044–0.109 L/h per kg, and volume 
of distribution (Vd) is 0.34–1.57 L/kg. 17 Indomethacin crosses the 
placenta leading to fetal serum concentrations that are greater than 
amniotic-fl uid levels. Nifedipine is a calcium-channel antagonist 
that induces vascular smooth muscle relaxation. Its absorption is 
rapid, but bioavailability is low due to fi rst-pass metabolism and 
conversion of 40% of the drug into inactive metabolites. 17,18 Aft er 
a 10-mg oral dose, the peak serum concentration is 38.6 ± 18 μg/L, 
T1/2 is 1.3 ± 0.5 hours; and plasma clearance is 2.0 ± 0.8 L/h per kg. 19 
Nifedipine also crosses the placenta and is found in the umbilical 
cord, fetal blood, and amniotic fl uid. Although unlicensed and 
with several contraindications to its use, including maternal side 
eff ects, magnesium sulfate is commonly used for tocolysis in the 
United States. Maternal serum concentrations do not correlate 
with tocolytic eff ect, therefore, the infusion rate of magnesium 
sulfate is titrated according to clinical response and side eff ects. 20 
With a 4-g intravenous loading dose of magnesium sulfate, the 
peak serum concentration is 5.56 ± 0.30 mg/dL; T1/2 is 610 ± 
14 minutes; and Vd is 15.6 L. 17 Magnesium sulfate crosses the 
placenta and is found in the amniotic fl uid and fetal compartment. 
Due to the limited amount of information available regarding 
the appropriate dosing and frequency of administration of these 
drugs, research into the PK and PD of tocolytics is necessary 
in order to more eff ectively treat PTL and improve neonatal 
outcomes through the prolongation of pregnancy. 
 How sweet it is—taking a second look at hypoglycemic agents 
in pregnancy 
 Gestational diabetes mellitus aff ects nearly 18% of pregnancies 
and is associated with signifi cant maternal, fetal, and neonatal 
complications. Oral hypoglycemic agents such as glyburide and 
206 VOLUME 4 • ISSUE 3 WWW.CTSJOURNAL.COM
 Haas et al.  Pharmacotherapy and Pregnancy 
metformin are commonly used for the treatment of gestational 
diabetes based on the randomized trials demonstrating similar 
outcomes to insulin, in addition to their easy route of administration 
and schedule. 21,22 Th e physiologic changes that occur during 
pregnancy such as alterations in CYP2C9, CYP3A, and CYP2C19 
activities have been shown to alter the PK of glyburide, which may 
have signifi cant implications for the optimum dosage range during 
pregnancy. 23 However, glyburide has been shown to cross the 
placenta, therefore, evaluation of alternate dosage regimens above 
the currently used dosage range (up to 10 mg twice daily) will 
need to consider fetal and neonatal safety. 23 Th e changes in renal 
fi ltration as well as active renal transport during pregnancy result 
in altered PK of metformin. 24 Th e changes may or may not result 
in the need to alter the metformin dosage range during pregnancy. 
In addition to considerations regarding dosage range optimization 
for gestational diabetes mellitus treatment, medication selection 
optimization requires further evaluation. Th e heterogeneity in 
underlying abnormalities in insulin sensitivity and beta-cell 
responsivity 23 for women with gestational diabetes will likely 
play a role in individual response to the various hypoglycemic 
agents. 
 NIH update on pregnancy pharmacology programs 
and the OPRUs 
 In the United States, more than 50% of women take one or more 
medications during their pregnancies. But most of the medications 
do not have adequate dosage and safety recommendations for the 
pregnant women, which may adversely impact the health of both 
pregnant women and their unborn babies. Th e Obstetric-fetal 
Pharmacology Research Units (OPRU) network was funded by 
the National Institute for Child Health and Human Development 
in 2005 and was recompeted in 2009 to serve as a national resource 
for pharmacologic studies of drug disposition and eff ect during 
normal and abnormal pregnancies. 
 Th e OPRU network takes a multidisciplinary approach to 
maternal and fetal therapeutics, pairing clinical and basic science 
collaborative researchers within the sites and across the networks. 
During the fi rst funding cycle, the OPRUs performed a study on 
glyburide’s eff ects during and aft er pregnancy 23 and on the PKs 
of 17alpha-hydroxyprogesterone caproate in pregnancy to reduce 
the risk of recurrentPTB. Th e OPRU network also conducted 
opportunistic studies to determine the PK of the drugs that are 
being used for medications in women during their pregnancies. 
Th e currently funded sites are Indiana University, University of 
Pittsburgh, University of Texas Medical Branch in Galveston, and 
University of Washington, along with a Data Coordinating Center 
at Research Triangle International. Each site has unique clinical 
and basic science strengths that synergize across the network 
to be able to advance the fi eld. In the current round of funding, 
which began in 2010, there are currently two new clinical trials 
moving forward: a trial of glyburide and metformin therapy for 
gestational diabetes and a study of diff erent progestins for the 
prevention ofPTB. 
 Breast-feeding and medication in mother’s milk 
 Medications are commonly taken by women during pregnancy 
and postpartum to treat diseases that are specifi cally related to 
pregnancy or preexisting medical conditions. Just as ethical and 
medical considerations are necessary for pharmacotherapy in 
pregnancy, considerations are necessary to avoid the risk of drug 
exposure to the infant by means of breast-milk transfer. Current-
product labeling allows for the description of drug excretion to 
human milk and discusses the risks for serious adverse events. 
Th e case of the serious adverse event from codeine described by 
Koren’s group highlights the importance of human and genetic 
research in the area of human lactation. 25 Th e FDA’s upcoming 
pregnancy-labeling rule will include sections on risk summary, 
clinical considerations, and known data. Th e most valuable study 
data to help populate the new pregnancy label will come from 
studies that look at the total infant exposure, measured by ratios 
of areas under the concentration-time curve of drug in maternal 
plasma as compared with breast milk. Clinical lactation studies 
should be geared toward identifying the risk of drug exposures 
to neonates, the total infant daily dose, and the safety and adverse 
events due to drug exposure. While there is a paucity of this 
type of data currently, more is on the way. With more data, it 
will be possible to help nursing mothers and their physicians in 
counseling and in planning clinical investigations. 
 Ethical challenges in consenting pregnant women 
for medication research 
 Society’s approach to the protection of human subjects in 
research might be captured best by the image of a slowly swinging 
pendulum. In the early years (post-Nuremberg Code), a strong 
protectionist ethic prevailed when concern about minimizing 
risk was so pervasive that, to paraphrase Hans Jonas, society was 
encouraged to accept slower progress in the conquest of disease 
if it meant that human dignity and important moral values were 
retained. As time passed and experience progressed, the absolutist 
stance was relaxed, evidenced by the somewhat more permissive 
 Declaration of Helsinki that permitted (where Nuremberg did 
not), research on vulnerable persons, including children. Th e 
pendulum has rarely swung to a completely permissive (i.e., a 
rule-free) position. But eff orts to more carefully calibrate risk 
and to defi ne vulnerable populations in need of special additional 
protections have been underway for decades. Pregnant women, 
children, fetuses, and neonates are defi ned as “vulnerable” and in 
need of additional protection according to this reasoning and have 
at various times been either completely excluded from eligibility 
for research or been limited participants. But here too, times have 
changed and the pendulum has not remained static.  Th e NIH 
Policy and Guidelines on the Inclusion of Women and Minorities as 
Subjects in Clinical Research —Amended October 2001 26 is a clear 
statement on  how to include vulnerable persons. Consistent with 
the ethical principle of justice, the policy requires a justifi cation 
if these populations are to be excluded, suggesting that the 
pendulum’s current trajectory has come to rest at a position of 
moderate protectionism. 
 Medication research involving pregnant women may have 
been previously discouraged, but not now. One reason for the 
change in stance is the important role of informed consent as a 
gatekeeper. No one questions the value of a robust consent process. 
Where the challenges lie are at the level of quality and quantity 
of information: how much information do researchers need to 
disclose to subjects? Whereas it might seem self-evident that 
patients should be given as much information as possible, some 
research suggests that potential subjects do not actually understand 
or want much of the information before making decisions. Th is 
fi nding should give pause if applied to a medication study (do 
we really want to give less rather than more information?), but, 
in other areas such as the development of biobanks, changes 
in the practice of informed consent are already underway. 
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Vanderbilt’s BioVU biobank is an opt-out system (not unlike 
Spain’s presumed consent approach to organ transplantation) 
where research subjects must indicate a preference not to have 
data or information used in research. 
 Th e pendulum is also infl uenced by researchers serving in 
multiple roles (e.g., health care provider and researcher), as do 
many health care providers. As demonstrated in a recent study, 
there is oft en a disconnect between what health care providers 
will support for their patients and for themselves. 27 Can we rely 
on the quality of the data that help us inform decisions? If the 
data are not robust, then are decisions truly informed? We also 
know that research is not confi ned by national borders. Research 
must also be sensitive to the social, political, and cultural issues 
in diff erent locations. For instance, in parts of Kenya, women 
are culturally not allowed to consent for themselves. It is only 
in discussing and working on these ethical challenges that 
we can continue to see progress and meaningful and ethical 
benefi ts to human subjects’ research in general, and specifi cally 
in pregnancy. 
 FDA and Maternal Health Update: Gathering and Com-
municating Data about Drug Use during Pregnancy and 
Lactation 
 Th ere are more than 60 million American women of reproductive 
age, and about 10% of them become pregnant each year, only 
50% of these pregnancies are planned. Pregnant women may 
require continued drug treatment for chronic conditions or 
treatment for new conditions that arise during pregnancy. While 
pregnant women use an average of four or fi ve prescription drugs 
during pregnancy, they are usually excluded from clinical drug 
trials conducted prior to approval for marketing. Research and 
knowledge gaps remain following FDA approval and marketing 
of most drugs because studies of maternal and fetal eff ects and 
the amount of drug in human milk are not routinely studied. In 
turn, prescribers have little or no scientifi c evidence with which 
to inform clinical care, prescribing, and counseling for women 
of childbearing potential. 
 Over the past decade, new legislative authorities (FDA 
Amendments Act of 2007), multiple FDA initiatives, and eff orts 
in the scientifi c and ethics communities have coalesced into 
a movement to improve data gathering and communication 
about drug use during pregnancy and lactation. Th e Pediatric 
and Maternal Health Staff  (PMHS) in the Offi  ce of New Drugs 
at FDA’s Center for Drug Evaluation and Research focuses on 
drug development and drug safety issues related to the use of 
medications in children, adolescents, and women of childbearing 
potential, especially those who are pregnant and breast-feeding. 
FDA’s activities currently focus on three areas:
 
(1)  Development, clearance, and publication of the final 
regulations for pregnancy and lactation labeling for 
prescription drugs and biological products. 
(2)  Development and publication of guidance for the drug 
development industry and FDA reviewers (e.g., PK during 
pregnancy and the postpartum period, clinical lactation 
studies, pregnant women in clinical trials:  scientifi c and 
ethical considerations). 
(3)  Working with review divisions in the Offi  ce of New Drugs to 
identify drugs that should be approved with requirements to 
study the eff ects of the drug in pregnant women and/or the 
amount of drug in human milk. 
 Th e new proposed regulations for pregnancy and lactation 
labeling for prescription drugs were published in May 2008. FDA 
received comments on the proposed regulations during a 90-day 
public comment period. Th ese comments were considered and 
utilized by the FDA in development of the fi nal regulations for 
publication, a process that is currently underway. Th e proposed 
regulations call for eliminating the confusing and oft en misused 
pregnancy categories (A, B, C, D, and X) from drug labeling for 
all drugs and will revise the content and format of pregnancy 
and nursing mothers labeling subsections for prescription 
drugs approved on or aft er June 30, 2001. Drug manufacturers 
will be able to voluntarily adopt the new format and content 
requirements for older drugs. The pregnancy subsection 
of labeling will include information about whether there is 
an ongoing prospective cohort study (pregnancy exposure 
registry) evaluating the eff ects of the drug in pregnant women 
using the drug therapeutically. Th is will be followed by a  Risk 
Summary based on available human and animal data; a  Clinical 
Considerations section; and a  Data section that includes detailed 
information about the studies supporting the information in 
the  Risk Summary and  Clinical Considerations . Th e  Clinical 
Considerations section provides information to prescribers to 
support clinical decision making and management. It includes 
information about the known risk to a pregnant woman and her 
fetus from the disease or condition the drug is intended to treat, 
dosing adjustments needed during pregnancy, maternal adverse 
reactions unique to or exacerbated by pregnancy, and potential 
neonatal complications and needed interventions. Th e  Clinical 
Considerations section also includes information about known 
eff ects of the drug on labor and delivery. 
 FDA’s greatest communication tool is drug labeling, but 
developing informed and balanced labeling is a complicated 
and challenging process. Th is is especially true for information 
about medication use during pregnancy and breast-feeding 
because there is oft en limited information at the time that a 
drug is approved. It is critical to our nation’s public health to 
identify and communicate the risks and benefi ts of medication 
treatment for mothers and their fetuses/infants. Th is can only be 
accomplished with thorough scientifi c review of available human 
and animal data, identifi cation of ethical and scientifi cally sound 
approaches to gathering more human data on medication use 
during pregnancy and breast-feeding, and clear and clinically 
relevant communication of this information to prescribers 
through drug labeling. 
 New Frontiers in Nausea and Vomiting of Pregnancy 
 Nausea and vomiting of pregnancy (NVP) aff ects an estimated 
80% of all pregnancies. Th e condition has been trivialized in 
practice and research, assuming that it is merely an inconvenience. 
However, research in Motherisk has shown major impact on the 
quality of life of millions of women. 28 
 Treatment of symptoms of NVP has been challenged by 
limited research and less than optimal samples sizes to prove 
fetal safety. Th e drug most studied has been the combination 
of doxylamine and pyridoxine (vitamin B6). It is estimated that 
this antiemetic combination will reenter the American market as 
Diclectin® (a Canadian version of Bendectin®, used in the United 
States until 1982). Recent studies have shown that NVP associated 
with refl ux symptoms is more severe, and that treatment of refl ux 
symptoms with either H 2 blockers or Proton Pump Inhibitors 
alleviates the severity of NVP. 29 
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 Cord blood (and tissue) banks—can they inform future 
therapies? 
 Maternal and fetal/newborn tissues (e.g., cord blood, placenta) 
are readily available, oft en discarded, and useful for both clinical 
and research needs. Th ere is potential for cord blood and tissue 
banks to be repositories of cells and tissues for pharmacology 
research. Areas in which cells/tissues are used for maternal/fetal 
pharmacology research include transporter cellular/molecular 
biology; growth factor production and signaling; enzyme 
polymorphism studies; and drug metabolism studies. At the 
present time, a variety of cell and tissue models, such as malignant 
cell lines, isolated mature cells and/or microsomes, and  ex vivo 
perfused tissues are used for this research. However, the extent 
to which these model systems represent normal maternal/fetal 
tissues is unclear, and problems also exist with standardization 
and reproducibility between laboratories. Th e use of primary 
stem/progenitor cells derived from maternal/fetal tissues provides 
potential solutions to some of these problems, since primary 
cultures can be isolated using standardized techniques, greatly 
expanded in culture, used to reproduce results using cells from 
the same donor instead of multiple donors, and widely distributed 
for validation of results in numerous laboratories. 
 Th e question remains regarding where these cells and tissues 
would be processed for widespread research use. Cord blood 
banks have been proposed as one potential source, since they 
routinely process and store cord blood hematopoietic stem cells 
for clinical use. However, cord blood banks perform minimal 
cell isolation and no culture/expansion since there is currently 
no clinical need for isolation and culture of hematopoietic cells, 
and in general process only cord blood and not other maternal/
fetal tissues. Alternatively, tissue banks are well suited to providing 
cells and tissues to the research community. Tissue banks can store 
whole tissues but also isolate specifi c cells and oft en expand these 
cells prior to (or aft er) banking. Primary cells from maternal/fetal 
tissues that are potentially available from tissue banks include 
mesenchymal stem cells (MSC) from cord blood, cord tissues 
(e.g., Wharton’s jelly), and placenta; endometrial (or uterine) 
regenerative cells (ERC); and human umbilical vein endothelial 
cells (HUVEC). MSC are expandable in culture to >10 12 cells 
or >30 population doublings, facilitating multiple reproducible 
experiments validated in many laboratories from a single donor. 
Placental MSC have been demonstrated to participate in placental 
tissue generation, maintenance, and repair, attesting to their utility 
as a model for normal tissues. HUVEC are more limited in their 
culture capacity than MSC and ERC, but are already widely used 
for pharmacologic research, particularly involving oxidative stress 
and vasogenic factors involved in pregnancy/labor. In summary, 
primary cells provided by tissue banks from maternal and/or 
neonatal tissues are readily available and expandable, are superior 
to immortalized malignant cell lines, may be able to mimic  in 
vivo conditions by coculture of cell types (e.g., HUVEC with 
placental MSC; maternal with fetal-derived MSC), and may be 
amenable to additional manipulation, such as syncytialization 
of trophoblasts in culture. Moreover, not only normal cells but 
cells from neonates with genetic defects can be isolated; these 
cells may provide additional cellular research models and disease 
insights. 
 Preeclampsia and hypertension—individualizing therapy 
 Antihypertensive therapy in pregnancy and preeclampsia have 
evolved as the data have driven more individualization. Th e risk 
of not intervening is severe hypertension and its adverse maternal 
sequelae. Th e risk of intervening too early is premature or small 
for gestational age babies. It is evident that treating hypertension 
in pregnancy prevents severe hypertensive crises. 30 
 Individualizing therapy based on maternal hemodynamics is 
based on the equation that Mean Arterial Pressure (MAP) = Cardiac 
Output (CO) × Total Peripheral Resistance (TPR)/80.  In order to 
control blood pressure, either the CO or TPR can be targeted by 
therapy. Additionally, simply because the majority of hypertensive 
pregnant women are in a vasoconstricted state does not mean that 
all subjects would benefi t from lowering resistance. Studies have 
demonstrated that controlling BP before women get pregnant 
can reduce preterm deliveries. A small study demonstrated that 
atenolol therapy led to smaller babies. 31 It is confi rmed that there is 
a trade-off  that as the BP is lowered, the birth weight does go down, 
however, there is less preterm delivery and respiratory distress 
syndrome . Individualizing therapy may actually indicate that it 
takes less drugs to control the BP as the pregnancy progresses. 
Hydralazine is a vasodilator that leads to a small increase in CO 
as the MAP decreases. Beta blockers such as atenolol decrease 
CO, leading to a decrease in MAP and a slight increase in TPR. 
Diuretics such as furosamide decrease CO in smaller amounts than 
beta blockers. Clonidine is a complex drug that has considerable 
variability in CO and TPR response. Th us, combination therapy 
can oft en achieve the normalization of maternal hemodynamic 
parameters that single-agent therapy is unable to provide. Individual 
variation in drug metabolizing enzymes may also play a role as 
certain drugs such as metoprolol are CYP2D6 substrates and can 
have profound diff erences in activities throughout pregnancy. 
Th e goal of the PK and PD principles in fostering individualized 
drug therapy for hypertension and preeclampsia is to promote 
maternal health, prevent PTB, and maintain fetal growth. Maternal 
hemodynamics can be used to eff ectively direct therapy to achieve 
these individualized pharmacotherapy goals. 
 Do not forget the baby—studying neonatal eff ects of drugs 
in pregnancy 
 Fetal development is an especially sensitive period, and 
alterations and interventions have the potential to produce 
lifelong consequences. As predicted by the fetal origins of adult 
disease hypothesis, it is becoming increasingly clear that altered 
fetal growth can signifi cantly increase the risk of adult onset 
diseases such as hypertension, coronary artery disease, and type 
II diabetes. It is then reasonable to be concerned that maternal 
exposure to drugs may have the potential to produce similar 
long-term consequences. 
 Th e use of antenatal steroids to reduce respiratory distress 
syndrome in premature infants is probably the best-studied 
fetal drug exposure. Multiple randomized controlled trials 
have demonstrated that antenatal steroids provide signifi cant 
benefi ts, including reductions in respiratory-distress syndrome, 
intraventricular hemorrhage, necrotizing enterocolitis, and death. 
In addition, there is signifi cant information about the eff ects 
of antenatal steroids beyond the neonatal period. Exposure to 
antenatal steroids has no detrimental eff ect in children or adults 
on hypothalamic pituitary axis function, growth, blood pressure, 
or cholesterol concentrations. Th ere is even a suggestion that 
blood-glucose concentrations may be lower in adults who have 
received antenatal steroids compared to those who have not. So 
for antenatal steroids, there is high-quality evidence supporting 
signifi cant neonatal benefi ts and no long-term negative eff ects; 
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it is unlikely that this amount or quality of information will be 
produced for most other maternal drug exposures. 
 A drug class of current interest is the selective serotonin 
reuptake inhibitors (SSRIs). Th ere are no available randomized-
controlled trials, but observational studies have raised concerns 
about SSRI exposure and increased risk of premature delivery, 
although untreated depression may have a similar effect. 
Neonatal-abstinence syndrome aft er  in utero exposure to SSRIs 
has been well documented, with approximately 30% of exposed 
infants having symptoms. A relationship between maternal use 
of SSRIs and persistent pulmonary hypertension of the newborn 
has also been observed; however, the increase in risk appears 
to be small, and not all studies have observed the relationship. 
Observational studies examining neurodevelopmental outcome 
aft er maternal use of SSRIs have not measured any adverse 
eff ects in children up to 6 years of age. However, the eff ects of 
fetal SSRI exposure beyond early childhood remain unknown. 
Some mechanism to evaluate the long-term eff ects of drugs in 
pregnancy is necessary; as electronic medical records become 
more prevalent, documenting maternal drug exposures in the 
medical record would be an important advance in evaluating 
long-term drug eff ects in children and the mothers. 
 Conclusion 
 As providers, pharmacists, FDA and NIH representatives, and 
patients make decisions every day about medication therapy in 
pregnancy, it is clear that more data are needed. Hypertension, 
diabetes, and PTL are just a few of the conditions that require 
drug therapy in pregnancy. Understanding the data through the 
current research, and upcoming pregnancy and lactation labeling 
changes, will aid in counseling pregnant women about their 
options. Cooperation and collaboration between government 
agencies, researchers, and people on the front lines of patient care 
will continue to strive to improve the care of pregnant women 
and their babies. 
 References 
 1.  Andrade  SE ,  Gurwitz  JH ,  Davis  RL ,  Chan  KA ,  Finkelstein  JA ,  Fortman  K, McPhillips H, Raebel 
MA, Roblin D, Smith DH, et. al .  Prescription drug use in pregnancy .  Am J Obstet Gynecol.  2004 ; 
 191 ( 2 ):  398–407 . 
 2.  Engeland  A ,  Bramness  JG ,  Daltveit  AK ,  Ronning  M ,  Skurtveit  S ,  Furu  K .  Prescription drug 
use among fathers and mothers before and during pregnancy. A population-based cohort study of 
106,000 pregnancies in Norway 2004-2006 .  Br J Clin Pharmacol.  2008 ;  65 ( 5 ):  653–660 . 
 3.  Updated Interim Recommendations for Obstetric Health Care Providers Related to Use of An-
tiviral Medications in the Treatment and Prevention of Infl uenza for the 2009-2010 Season. The 
Centers for Disease Control and Prevention .  2009 [ cited 2009 September 24 ];  Available from : 
 http://www.cdc.gov/H1N1fl u/pregnancy/antiviral_messages.htm . 
 4.  United States General Accounting Offi ce GAO/HRD-93-17. Women’s Health – FDA needs to 
ensure more study of gender differences in prescription drug testing .  1992 . 
 5.  Hebert  MF ,  Carr  DB ,  Anderson  GD ,  Blough  D ,  Green  GE ,  Brateng  DA, Kantor E, Benedetti TJ, 
Easterling TR .  Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and post-
partum .  J Clin Pharmacol.  2005 ;  45 ( 1 ):  25–33 . 
 6.  Andrew  MA ,  Easterling  TR ,  Carr  DB ,  Shen  D ,  Buchanan  ML ,  Rutherford  T, Bennett P, Vicini P, 
Hebert MF .  Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosa-
ge strategies .  Clin Pharmacol Ther.  2007 ;  81 ( 4 ):  547–556 . 
 7.  Freeman  MP ,  Nolan  PE  Jr ,  Davis  MF ,  Anthony  M ,  Fried K ,  Fankhauser  M, Woolsey RL, Moreno F . 
 Pharmacokinetics of sertraline across pregnancy and postpartum .  J Clin Psychopharmacol.  2008 ; 
 28 ( 6 ):  646–653 . 
 8.  Shields  KE ,  Wiholm  BE ,  Hostelley  LS ,  Striano  LF ,  Arena  SR ,  Sharrar  RG .  Monitoring outcomes 
of pregnancy following drug exposure: a company-based pregnancy registry program .  Drug Saf. 
 2004 ;  27 ( 6 ):  353–367 . 
 9.  Guidance for Industry Establishing Pregnancy Exposure Registries .  Rockville ,  MD :  U. S. Food 
and Drug Administration ;  2002 . 
 10.  Martin  JA ,  Hamilton  BE ,  Sutton  PD ,  Ventura  SJ ,  Menacker  F ,  Kirmeyer  S, Mathews TJ .  Births: 
fi nal data for 2006 .  Natl Vital Stat Rep.  2009 ;  57 ( 7 ), 102 pp . 
 11.  Hamilton  BE ,  Martin  JA ,  Ventura  SJ .  Births: preliminary data for 2008 .  Natl Vital Stat Rep. 
 2010 ;  58 ( 16 ):  1–17 . 
 12.  Yoder  SR ,  Thornburg  LL ,  Bisognano  JD .  Hypertension in pregnancy and women of childbea-
ring age .  Am J Med.  2009 ;  122 ( 10 ):  890–895 . 
 13.  Schatz  M ,  Dombrowski  MP .  Clinical practice. Asthma in pregnancy .  N Engl J Med.  2009 ; 
 360 ( 18 ):  1862–1869 . 
 14.  Yonkers  KA ,  Wisner  KL ,  Stewart  DE ,  Oberlander  TF ,  Dell  DL ,  Stotland  N , Ramin S, Chaudron 
L, Lockwood C.  The management of depression during pregnancy: a report from the Ameri-
can Psychiatric Association and the American College of Obstetricians and Gynecologists .  Obstet 
Gynecol.  2009 ;  114 ( 3 ):  703–713 . 
 15.  Briggs  GG ,  Nageotte  MP ,  editors .  Diseases, Complications, and Drug Therapy in Obste-
trics: A guide for clinicians .  Bethesda ,  MD :  American Society of Health-Systems Pharmacists ; 
 2009 . 
 16.  Tan  TC ,  Devendra  K ,  Tan  LK ,  Tan  HK .  Tocolytic treatment for the management of preterm 
labour: a systematic review .  Singapore Med J.  2006 ;  47 ( 5 ):  361–366 . 
 17.  Tsatsaris  V ,  Cabrol  D ,  Carbonne  B .  Pharmacokinetics of tocolytic agents .  Clin Pharmacokinet. 
 2004 ;  43 ( 13 ):  833–844 . 
 18.  Abernethy  DR ,  Schwartz  JB .  Calcium-antagonist drugs .  N Engl J Med.  1999 ;  341 ( 19 ):  1447–
1457 . 
 19.  Ferguson  JE  2nd ,  Schutz  T ,  Pershe  R ,  Stevenson  DK ,  Blaschke  T .  Nifedipine pharmacokinetics 
during preterm labor tocolysis .  Am J Obstet Gynecol.  1989 ;  161 ( 6 Pt 1 ):  1485–1490 . 
 20.  Madden  C ,  Owen  J ,  Hauth  JC .  Magnesium tocolysis: serum levels versus success .  Am J Obstet 
Gynecol.  1990 ;  162 ( 5 ):  1177–1180 . 
 21.  Langer  O ,  Conway  DL ,  Berkus  MD ,  Xenakis  EM ,  Gonzales  O .  A comparison of glyburide 
and insulin in women with gestational diabetes mellitus .  N Engl J Med.  2000 ;  343 ( 16 ):  1134–
1138 . 
 22.  Rowan  JA ,  Hague  WM ,  Gao  W ,  Battin  MR ,  Moore  MP .  Metformin versus insulin for the treat-
ment of gestational diabetes .  N Engl J Med.  2008 ;  358 ( 19 ):  2003–2015 . 
 23.  Hebert  MF ,  Ma  X ,  Naraharisetti  SB ,  Krudys  KM ,  Umans  JG ,  Hankins  GD, Caritis SN, Miodo-
vnik M, Mattison DR, Unadkat JD, et. al .  Are we optimizing gestational diabetes treatment with 
glyburide? The pharmacologic basis for better clinical practice .  Clin Pharmacol Ther  2009 ;  85 ( 6 ): 
 607–614 . 
 24.  Eyal  S ,  Easterling  TR ,  Carr  D ,  Umans  JG ,  Miodovnik  M ,  Hankins  GD, Clark SM, Risler L, Wang 
J, Kelly EJ, et. al .  Pharmacokinetics of metformin during pregnancy .  Drug Metab Dispos.  2010 ; 
 38 ( 5 ):  833–840 . 
 25.  Koren  G ,  Cairns  J ,  Chitayat  D ,  Gaedigk  A ,  Leeder  SJ .  Pharmacogenetics of morphine poiso-
ning in a breastfed neonate of a codeine-prescribed mother .  Lancet.  2006 ;  368 ( 9536 ):  704. 
 26.  NIH policy and guidelines on the inclusion of women and minorities as subjects in clinical re-
search .  2001.  Available at :  http://grants.nih.gov/grants/funding/women_min/guidelines_amen-
ded_10_2001.htm .  Accessed October 14, 2008 . 
 27.  Haas  DM ,  Wunder  K ,  Wolf  JG ,  Denne  SC .  Women’s health care providers’ attitudes toward 
research in pregnancy .  J Reprod Med.  2010 ;  55 ( 3-4 ):  108–114 . 
 28.  Mazzotta  P ,  Stewart  D ,  Atanackovic  G ,  Koren  G ,  Magee  LA .  Psychosocial morbidity among 
women with nausea and vomiting of pregnancy: prevalence and association with anti-emetic 
therapy .  J Psychosom Obstet Gynaecol.  2000 ;  21 ( 3 ):  129–136 . 
 29.  Gill  SK ,  Maltepe  C ,  Koren  G .  The effect of heartburn and acid refl ux on the severity of nausea 
and vomiting of pregnancy .  Can J Gastroenterol.  2009 ;  23 ( 4 ):  270–272 . 
 30.  Magee  LA ,  Elran  E ,  Bull  SB ,  Logan  A ,  Koren  G .  Risks and benefi ts of beta-receptor blockers 
for pregnancy hypertension: overview of the randomized trials .  Eur J Obstet Gynecol Reprod Biol. 
 2000 ;  88 ( 1 ):  15–26 . 
 31.  Butters  L ,  Kennedy  S ,  Rubin  PC .  Atenolol in essential hypertension during pregnancy .  BMJ. 
 1990 ;  301 ( 6752 ):  587–589 . 
